On Tuesday, Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), added 0.43% and closed at $2.35 in the last trading session. CTRV stock opened its last trade at $2.26 and after floating in a range of $2.16 to $2.49. The company’s Market capitalization is $150.54 million with the total Outstanding Shares of 53.66 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.76 and reached to max level of $2.65. The Earnings per Share of the company stands at $-0.64. ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, declared recently that following a positive recommendation from an independent Data Safety Monitoring Board (DSMB), the company has begun enrolling the next dosing group in its head-to-head Phase 2a dose-escalation study comparing the safety and efficacy of ContraVir’s CMX157 to tenofovir disoproxil fumarate (TDF, marketed by Gilead Sciences as Viread®) in patients with chronic hepatitis B (HBV). ContraVir anticipates to complete the remaining two escalation cohorts and report top-line results by year-end 2016.
The DSMB conducted an independent review of the safety, tolerability and pharmacokinetic profile of CMX157 from the accomplished 5 mg, 10 mg and 25 mg dosing groups of ContraVir’s ongoing, 28-day, Phase 2a study in HBV-infected patients. Based on CMX157’s favorable safety and tolerability in this study in addition to in a accomplished Phase 1b study in healthy volunteers, which dosed up to 100 mg of CMX157 per day, the DSMB approved proceeding to a higher dose in the ongoing Phase 2a dose escalation trial per study protocol.
“Coupled with our recent demonstration of clinical proof of concept for CMX157 in HBV patients, the DSMB’s confirmation of CMX157’s safety profile continues to build the case for this drug’s potential as a cornerstone for combination therapy to cure HBV,” said James Sapirstein, CEO of ContraVir. “We look forward to reporting final Phase 2a data by year end, and continue to believe that CMX157 has the ideal attributes needed for use as a component of a future combination drug strategy where drug-drug interactions put high demands on safety.”
Shares of Cypress Semiconductor Corporation (NASDAQ:CY), lost -1.12% and closed at $10.61 in the last trading session. CY stock opened its last trade at $10.65 and after floating in a range of $10.57 to $10.78. The company’s Market capitalization is $3.38 Billion with the total Outstanding Shares of 321.18 million. During the 52-week trading session the minimum price at which share price traded, registered at $6.30 and reached to max level of $12.48. The Earnings per Share of the company stands at $-2.10. Cypress Semiconductor Corp. (CY) will declare its third quarter 2016 earnings on Thursday, October 27, 2016 after the U.S. stock markets close and will discuss the results in a conference call that day at 1:30 p.m. Pacific Daylight Time.